Page 144 - Biomarkers for risk stratification and guidance in heart failure

Prognostic impact of change in NT-proBNP versus change in eGFR.
19. de Silva R, Nikitin NP, Witte KK et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European heart journal 2006;27:569-81.
20. Haase M, Muller C, Damman K et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contributions to nephrology 2013;182:99-116.
21. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
22. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study \[CONSENSUS\] Trial). The American journal of cardiology 1992;70:479-87.
23. Rossignol P, Cleland JG, Bhandari S et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012;125:271-9.
24. Vardeny O, Wu DH, Desai A et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). Journal of the American College of Cardiology 2012;60:2082-9.
25. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
26. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-72.
27. Breidthardt T, Socrates T, Noveanu M et al. Effect and clinical prediction of worsening renal function in acute decompensated heart failure. The American journal of cardiology 2011;107:730-5.
28. Pascual-Figal DA, Domingo M, Casas T et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. European heart journal 2008;29:1011-8.
29. Troughton RW, Frampton CM, Brunner-La Rocca HP et al. Effect of B-type natriuretic peptide-guided
treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-
analysis. European heart journal 2014. 6
30. Berger R, Moertl D, Peter S et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. Journal of the American College of Cardiology;55:645-53.
31. Januzzi JL, Jr., Rehman SU, Mohammed AA et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology;58:1881-9.
32. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. Journal of the American College of Cardiology 2007;49:1733-9.
33. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
34. Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. Journal of the American College of Cardiology 2009;55:53-60.
35. Pfisterer M, Buser P, Rickli H et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA : the journal of the American Medical Association 2009;301:383-92.
36. Felker GM, O’Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circulation Heart failure 2009;2:56-62.
37. Maeder MT, Mueller C, Pfisterer ME, Buser PT, Brunner-La Rocca HP. Use of B-type natriuretic peptide outside of the emergency department. International journal of cardiology 2008;127:5-16.
143